ARYX THERAPEUTICS COMPLETES SERIES E FINANCING

ARYx Therapeutics Inc., a private drug discovery and development company, announced today that it has completed a $30.4 million Series E financing led by Ascent Biomedical Ventures. The company plans to use the funds to continue developing its three clinical programs, ATI-2042, ATI-7505 and ATI-5923 through to proof of concept Phase 2 data. The company expects to seek partnerships for each of its products upon successful proof of concept.
American Venture Magazine